Notably, the top candidate drug, MW-STK33-97, was previously identified by us as one of the leading compounds capable of neutralizing a detrimental gene program in macrophages exposed to the macroenvironment of acute myocardial infarction patients (38). The gene discussed is STK33; the disease is acute myocardial infarction.